Milestone Pharmaceuticals (NASDAQ:MIST) executives highlighted the company’s transition to commercialization during a ...
Expands institutional footprint with potential penetration of more than ~ 60% of the U.S. market, while expanding reach across EMS providers and ...
GAITHERSBURG, Md., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into an agreement to obtain exclusive commercial rights in the U.S. and ...
Inclusion of neffy on Express Scripts commercial formularies was effective November 22, 2024 and expands access to patients and caregivers managing Type 1 Allergic Reactions SAN DIEGO, Dec. 19, 2024 ...
Milestone Pharmaceuticals announced a Commercial Launch Plan investor event, indicating proactive engagement with investors and transparency about its upcoming strategies. The event will detail the ...
Detailed price information for Esperion Theraptc (ESPR-Q) from The Globe and Mail including charting and trades.
The first non-injectable emergency treatment for allergies is anticipated to hit shelves following FDA approval of the neffy epinephrine nasal spray. The product from ARS Pharmaceuticals, previously ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results